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Interest in amyloidogenesis has exploded in recent years, as scientists recognize the role of amyloid protein aggregates in degenerative diseases
such as Alzheimer's and Parkinson's disease. Assembly of proteins or peptides into mature amyloid fibrils is a multistep process initiated by
conformational changes, during which intermediate aggregation states such as oligomers, protofibrils, and filaments are sampled. Although once it
was assumed that the mature fibril was the biologically toxic species, more recently it has been widely speculated that soluble intermediates are the
most damaging. Because of its relevance to mechanism of disease, the paths traversed during fibrillogenesis, and the kinetics of the process, are of
considerable interest. In this review we discuss various kinetic models used to describe amyloidogenesis. Although significant advances have been
made, construction of rigorous, detailed, and experimentally validated quantitative models remains a work in progress. We briefly review recent
literature that illustrates the interplay between kinetics and amyloid–membrane interactions: how do different intermediates interact with lipid
bilayers, and how does the lipid bilayer affect kinetics of amyloidogenesis?
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amyloidogenesis in particular, has exploded in the past dozen
years, as scientists recognize the role of protein aggregates in a
number of degenerative diseases. Arguably, beta-amyloid
peptide (Aβ) has received the most attention because of its
importance in Alzheimer's disease pathology. Other amyloido-
genic proteins of note include α-synuclein, the prion proteins,
transthyretin, insulin, and polyglutamine-containing peptides or
proteins. The difference in thermodynamic stability of folded,
unfolded, andmisfolded proteins is not large, and the same forces
(e.g., hydrogen bonding, hydrophobic effect, electrostatics)
control both native folding and non-native misfolding. Reason-
ing from this basis, and collating data from numerous
experiments, it now appears that given modest disturbances
(e.g., as seemingly innocuous as a single-point mutation [1], or a
change in salt concentration [2]), nearly any polypeptide chain
can be driven towards misfolding and aggregation [3]. Our focus
in this review is particularly on the kinetics of amyloid formation.
Given the enormous depth and breadth of the recent amyloid
literature, this review is not encyclopedic but idiosyncratic.
1. Morphologies and methods
Kinetics is concerned with the pathway by which a
monomeric protein or peptide converts to amyloid fibrils, and
the rate at which fibrillogenesis proceeds. To address the
question of the kinetic pathway, we need to answer the
questions: What intermediates are observed? What are their
size, structural, and morphological characteristics? These
questions are not strictly academic, because there is consider-
able evidence that the size, structural features, and morphology
of the aggregated species are the key determinants of toxicity
[4]. An increasingly popular hypothesis is that intermediates in
the aggregation pathway, rather than the mature insoluble
fibrils, are the most toxic species [5–11]. If the kinetic
intermediates are toxic, then clearly the link between amyloid
formation and disease cannot be understood in the absence of an
understanding of the kinetics of amyloidogenesis. Elucidation
of the fibrillogenesis kinetics will contribute to the development
of new therapeutic strategies based on altering rates of
association. For example, if soluble aggregates but not
monomer nor mature fibril are toxic, then compounds that
sequester the monomer [12] and arrest oligomerization [13,14],
or conversely that accelerate conversion of intermediates to
mature fibril [15–17], may be of therapeutic interest.
1.1. Conformational and aggregation states
Several different conformational and aggregation states are
observed with amyloid proteins. The casual reader is stronglycautioned: the field is littered with vague, inconsistent, and even
contradictory nomenclature. The tasks of interpreting experi-
mental data and of comparing outcomes from different studies
are made more daunting by the fact that a plethora of
experimental methods is used to detect and characterize various
conformation and aggregation states. The definitions we have
chosen should not be construed as “the last word”, nor can it be
assumed when reading the primary literature that the nomen-
clature is the same as what we have chosen.
Monomers may have native or non-native secondary
structure. For some amyloidogenic peptides such as Aβ or
α-synuclein, the monomeric peptide is disordered, but is likely
not a true random coil. For example, solution NMR revealed
that monomeric Aβ is mostly extended but possesses regions
of β-strand and turn that appear to be retained in the fibrillar
structure [18]. Similarly, residual order was detected in Raman
spectra of a-synuclein [19], and molecular dynamic simula-
tions predict that polyglutamine monomers adopt a restricted
conformational ensemble that includes extended and compact
populations [20]. The native fold of monomeric amyloidogenic
proteins is not restricted to a particular structure: it may be α-
helical (e.g., apomyoglobin [21] or prion protein [22]), β-sheet
(e.g., immunoglobulin light chain [23]), or a mix. Several
well-known amyloidogenic proteins exist stably as a defined
native oligomer, for example, the homotetrameric protein
transthyretin, or the zinc-stabilized insulin hexamer. Dissocia-
tion to the monomer is typically required for conversion to
amyloid [24–26]; in these cases the monomer may be altered
conformationally from the native fold and is generally not stable.
Oligomers are globular aggregates that generally lack a well-
defined secondary structure. Some have argued that oligomers
are akin to micellar structures, with cylindrical or spherical
shape [27]. The sizes and conformational characteristics of
oligomers are quite variable. For example, Aβ was observed to
form both small spherical oligomers of about 5 nm in diameter
with molar masses in the 20–50 kDa range [6] as well as large
spherical oligomers with diameters around 15 nm and molar
masses approaching 1 million Da [28]. Small spherical
oligomers have also been reported with amyloidogenic peptides
including insulin and prion peptide fragment [5]. Globular
assembles, lacking defined structure and heterogeneous in size,
have been observed in a variety of preparations of proteins
containing polyglutamine domains [29,30]. Whether oligomers
are a direct intermediate to structured fibrils, an off-pathway
byproduct, or an intermediate towards amorphous aggregates,
remains uncertain. With Aβ [27] and with polyglutamine-
containing proteins [31], the evidence points towards these
oligomers being on-pathway. On the other hand, β-sheet
oligomers were detected in a study of prion protein assembly,
but the authors suggested that the oligomer is “off-pathway”
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fibril [32].
We will define protofibrils as linear (as opposed to globular)
aggregates that appear early in the amyloid pathway. Proto-
fibrils may share structural epitopes with oligomers, and may be
highly toxic [5]. Like oligomers, protofibrils lack the well-
defined secondary structure of filaments and fibrils. There is
substantial variability in the use of the term in the literature. As
an example, Aβ protofibrils detected by atomic force micro-
scopy were 4 nm in height, with a periodicity of about 20 nm,
and lengths of 20 nm to 200 nm or longer [33], whereas Aβ
protofibrils imaged by TEM were described as “curvilinear
structures of 4–11 nm diameter and <200 nm length” [11].
Protofibrils grow by monomer addition at the tip, incorporation
of small spherical oligomers, and/or by end-to-end coalescence
[33]. These structures are generally considered to be inter-
mediates in the amyloid formation pathway.
Protofilaments and filaments are linear aggregates with
definite β-sheet structure. Aβ protofilaments are typically 2.5 to
3.5 nm diameter [34], while at neutral pH a transthyretin mutant
associates into protofilaments of ∼6 nm diameter and about
50–100 nm in length [35]. The distinction between protofila-
ments and filaments is not sharply defined; generally, filaments
are elongated protofilaments. Protofilaments are distinguished
from protofibrils in that the structural characteristics of the
former are closer to those of fully mature fibrils (although again,
this is not a universally used distinction). Some researchers use
the term protofilaments only to characterize structural subunits
of fibrils that do not exist independently of the fibrils.
Fibrils are typically 7–12 nm in diameter, 1 μm or more in
length, with definite β-sheet structure. They typically appear to
be composed of a few (2–6) filaments that may be wrapped or
twisted around each other with regular helicity [36]. Formation
of fibrils probably involves cooperative association of proto-
filaments or filaments, and possibly additional conformational
changes as well. Generally fibrils are fairly straight and linear,
but occasionally have some branching. The notion of structural
polymorphism has surfaced recently, as it becomes clear that
there may be multiple alternative fibril morphologies (e.g.,
twisted or not, branched, even circular) [37–39]. Fibrils tend to
associate further into bundles [4]. Mature fibrils are the
insoluble end product of amyloidogenesis.
Large nonfibrillar aggregates are observed in some
preparations alongside amyloid fibrils. These nonfibrillar
aggregates are sometimes considered to be amorphous [40],
but may have some β-sheet content [4], although they lack the
obvious regular propagating structure of fibrils.
1.2. Experimental methods
Many different techniques are used to characterize amyloi-
dogenesis, and interpreting the results can sometimes be likened
to the proverbial “six blind men and an elephant”. The
experimental methods used influence the type of aggregates
that one might observe, and report on different properties of the
aggregates. As an example, simple turbidity and dye-binding
(e.g., thioflavin T or Congo red) assays are very popular asmeasures of kinetics of aggregation. These techniques, how-
ever, are reliably sensitive only to fibrils. They do not detect
smaller oligomers; protofibrils or filaments respond variably
[11,41,42]. The lack of a signal in these assays is frequently
taken as an indicator that the protein of interest remains
monomeric during a “lag time”, but this may be an erroneous
interpretation of the data, as oligomers, protofibrils, and/or
filaments can form rapidly during the putative “lag time” (see
for example [43,44]). Additionally, the signal intensity is
proportional to the mass of aggregates and not to its size; a
plateau in the signal may indicate that the conversion of non-
fibrillar to fibrillar protein is complete but does not necessarily
indicate that equilibrium is reached, as the size of the aggregates
may continue to grow.
Structural information is obtained from physical techniques
such as circular dichroism, solution-phase [18] and solid-state
NMR [45], H/D exchange, limited proteolysis coupled to mass
spectroscopy [46], and X-ray diffraction [47,48], as well as
biochemical approaches such as scanning alanine mutagenesis
[49]. Each of these methods has contributed important structural
clues. None, however, are particularly well adapted towards
examination of kinetic issues. Morphological data is obtained
primarily by electron microscopy and atomic force microscopy.
Stunningly detailed images have been obtained (see for example
[50,51]). Care must be taken in interpreting imaging data;
smaller aggregates in particular may be absent on EM images
but readily detectable by AFM. Both techniques may be used
for qualitative kinetic purposes, to examine for example how
morphology develops over time, but quantitation of the mass of
aggregates versus time is not reliable. Methods such as size
exclusion chromatography and laser light scattering are useful
means of obtaining kinetic data on both mass and size of
aggregates prior to onset of insolubility [52], but do not provide
high-resolution structural information. Surface plasmon reso-
nance and similar techniques have proved useful for examining
assembly kinetics [53,54], with the caveat that one of the
binding partners must be immobilized. Multiple experimental
measures, and recognition of the limitations of each, are crucial
for clear analysis of the whole “elephant”.
2. Pathways of amyloid formation
The aforementioned techniques have been used to examine
the pathways by which a wide variety of peptides/proteins
undergo self-association into amyloid fibrils. A succinct, but
somewhat oversimplified, description of four general mechan-
isms of amyloidogenesis appears in reference [55]. It is useful to
consider mechanisms of initiation and mechanisms of growth
separately. Broadly speaking, fibril initiation may occur by (1) a
kinetically or thermodynamically unfavorable conversion of
monomer to a “nucleus”, which may be a conformationally
altered monomer or oligomer, (2) a collision between two
monomers that converts one or both to an amyloid-competent
conformation, or (3) association of monomer into a non-
structured oligomer, followed by conformational conversion to
a structured oligomer. Fibril growth may proceed via (1)
addition of a non-amyloid monomer to a pre-existing structured
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and lock” mechanism), (2) indefinite self-association of
amyloid-competent monomers into structured oligomers and
larger aggregates, or (3) association of oligomers into larger
aggregates. Lateral alignment of filaments into fibrils, end-to-
end association of shorter fibrils, and bundling of fibrils, are
further maturation processes that may need to be considered for
a full description of fibril kinetics.
In this section we briefly mention examples of these
studies. This is not intended to be a comprehensive summary
of the literature, but rather illustrations of the diversity of
amyloidogenic proteins and pathways. There are important
differences in the starting materials that may strongly influence
the subsequent pathways. In particular, some peptides (e.g.,
Aβ, α-synuclein) are natively unfolded, other proteins (e.g.,
lysozyme) are natively folded monomer; still others (e.g.,
transthyretin, insulin) are natively multimeric. Still, there are
many commonalities. We will briefly describe the pathway of
amyloid formation for 4 systems: Aβ, prion protein, insulin,
and transthyretin.
2.1. β-amyloid (Aβ)
Aβ is a 4 kDa peptide released by proteolysis from the
membrane-spanning amyloid precursor protein, containing both
extracellular and transmembrane domains from its precursor. At
micromolar concentrations and in buffers at physiological pH
and ionic strength, disordered Aβ monomers spontaneously
undergo a coil to β-sheet transition and self-associate. It has
been suggested that a random coil to helix transition is an early
step in amyloid formation from Aβ [56], although it is difficult
to reconcile this finding with the β-sheet structure of amyloid.
Intermediates including dimers [57], small oligomers [58] and
protofibrils [33] have been detected. The oligomers and
protofibrils are generally believed to serve as building blocks
towards fibrils [33]. The mature fibril, consisting of 5–6
filaments, is ∼10 nm in diameter and unbranched, and can
reach lengths of 1 μm or more.
2.2. Prions
Prions are remarkable entities: entirely proteinaceous, yet
infectious. Most in vitro studies have worked with recombinant
prion protein (PrP) or PrP fragments. The native conformation
is predominantly helical; the denatured polypeptide refolds in
parallel paths to either the native α-helix, or to the β-sheet
amyloidogenic conformation. Folding to the native helix is
kinetically favored while the amyloid form is thermodynami-
cally favored [22]. Recombinant mouse PrP assembles into two
populations of soluble oligomers: large oligomers with a helix-
rich native-like secondary structure that is unstable in urea, and
small (4–5 nm diameter, containing about 8–15 monomers)
stable spherical oligomers with partial conversion to an
intermolecular β-sheet secondary structure [59]. The β-sheet
oligomers are believed by some researchers to be “off-pathway”
from amyloid fibril formation, and not fibrillar substructures
[32]. A model has been proposed of reversible transition ofnative protein N to unfolded polypeptide U, and irreversible
conversion of U to misfolded U*, with U* assembling into the
small oligomers and N forming the large oligomers [59].
2.3. Insulin
Aggregation of insulin is a nagging problem in manufacture
and delivery of this important drug. Insulin is a small protein
with a stable, predominantly helical native fold; it is typically
formulated as a zinc-stabilized hexamer. Conversion to amyloid
fibrils is preceded by loss of the stable quaternary structure.
Under acidic conditions, insulin hexamers dissociate, which
initiates aggregation. There are conflicts in the literature
regarding whether oligomeric intermediates are present prior
to fibril formation; discrepancies may be due to differences in
solvent or in insulin source. At pH 2 and 37 °C, bovine insulin
remained stable with a long lag time during which no aggre-
gates were detectable, by thioflavin T or laser light scattering,
followed by explosive growth of very large, precipitable aggre-
gates [60]. With human insulin at pH 1.6 and 60 °C, both
conventional amyloid fibrils and large clusters of aggregates
were detected; oligomers were present during the apparent lag
phase [61]. These data supported a model of insulin growth that
includes elongation at the tip as well as lateral assembly [61]. In
20% acetic acid, insulin assembled into oligomeric intermedi-
ates of non-native β-sheet rich structure, then underwent further
additional conformational changes to a second intermediate,
prior to the appearance of fibrils [62]. High resolution atomic
force microscopy of insulin at 60 °C and pH 1.6, identified
transient amorphous aggregates prior to appearance of fibrils
[37]. Mature fibrils emerged from both monomers/oligomers
stacking on protofilaments as well as protofilament-protofila-
ment lateral alignment [37].
2.4. Transthyretin
Transthyretin is a homotetrameric protein with a predomi-
nantly native β-sheet fold. Several mutants have been
identified, some of which are associated with amyloid disease.
The transthyretin variant L55P, associated with an aggressive
amyloid disease, associates into protofilaments at neutral pH
and fibrils at acidic pH [35]. Aggregation proceeds by
dissociation of the tetramer to monomer, conversion of the
monomer to a slightly different (but still β-sheet) conformation,
then growth to filaments and fibrils [26,35]. As with insulin,
loss of native quaternary structure is believed to be a
prerequisite for conversion to an amyloidogenic conformation.
The fibrils are laterally assembled four-filament structure.
Protofilaments are distinguished conformationally from fila-
ments, and may not necessarily convert to true amyloid
filaments/fibrils [35].
3. Quantitative “classical” kinetic models
Quantitative kinetic models are useful for extracting mechan-
istic information from experimental data, or for predicting the
effect of variables such as concentration on aggregation. In this
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models that treat monomers and aggregates as chemical species
participating as reactants or products in chemical reactions.
Several variations on this theme are described; these are shown
schematically in Fig. 1.
3.1. Nucleated polymerization
In nucleated polymerization, it is assumed that initial
assembly of monomer to a “nucleus” is unfavorable, either
because of slow kinetics or unfavorable equilibrium. The
nucleus rapidly elongates through monomer addition.
We will designate monomers as M, aggregates of n
monomers as An, and the number of monomers in the nucleus
as n*. In one embodiment of the nucleated polymerization
model, the nucleus is postulated to be in thermodynamic
equilibrium with the monomer:
n*M X An* Reaction ðR1Þ
with an equilibrium constant Kn ¼
½An*
½M n* that is small. (If the
nucleus:monomer concentration ratio is described by an
equilibrium constant, the reaction must be at equilibrium-
meaning that both forward and reverse reactions are fast relative
to subsequent elongation steps! This point is sometimes
confused in discussions of nucleated polymerization.)
For n>n*, monomer addition reactions are postulated to be
irreversible, independent of aggregate size, and described by a
single rate constant ke.
M þ An Y
ke
Anþ1; nznT Reaction ðR2Þ
If we define a molar concentration of fibrils as
½F ¼ Pl
j¼nTþ1
½Aj, and assume that the nucleus concentration isFig. 1. Three postulated mechanisms of amyloidogenesis. (Top) In nucleated
polymerization, the assembly of monomer into a nucleus of n* monomers
(illustrated here as containing 4 monomers) is either kinetically or thermo-
dynamically unfavorable. Further elongation occurs by irreversible addition of
monomer. Shading is used simply to indicate a specific monomer. (Middle) In
monomer-directed conversion, the unimolecular conversion of an “amyloid-
incompetent” monomer (circle) to an “amyloid-competent” monomer (triangle)
is slow. Bimolecular collision of an amyloid-competent monomer with an
amyloid-incompetent monomer results in rapid conversion of incompetent
monomer to competent. The amyloid-competent monomers proceed to assemble
into amyloid fibrils. (Bottom) In templated assembly, binding of a monomer
(circle) to a pre-existing amyloid fibril stabilizes the bound monomer in an
alternate conformation (triangle). Adapted from [55].negligible relative to the fibril concentration, then the infinite set
of reactions (R1) and (R2) is described by two coupled differ-
ential equations:
 d½M 
dt
¼ ke M½  F½  ð1Þ
d½F
dt
¼ keKn

M
nTþ1 ð2Þ
Awidely-used simplified analysis based on this mechanism is
described in [63]. (Ref. [63] also discussesmore general cases than
the one presented here.) Essentially, at early times the concentra-
tions of species are taken to be constant and equal to their initial
value. These simplifications lead to a very appealing equation:
M0½   M½  ¼ 12 k
2
e Kn

M0
nTþ2
t2 ð3Þ
where [M] is the monomer concentration at time t and [M0] is the
initial monomer concentration. Fitting this equation to data where
[M] is measured as a function of time, at several [M0] should
therefore yield values for ke, Kn, and n*. This approach has been
used for example, to analyze kinetic data for polyglutamine
peptide aggregation; the authors concluded for this system that
n*=1, that is, that the nucleus is a monomer [64].
A cursory analysis leads to the realization that there is a
practical problem inherent in this methodology: the assumption
that [M]–[M0] (which makes integration of the differential
equation simple) means that the experimental measurements
must be very accurate, since the equation is only applicable
when
½M0  ½M 
½M0 << 1. In Fig. 2, we illustrate that the solutions
of the coupled differential equations and the simplified algebraic
equation diverge at ∼10% loss of monomer. Given the
widespread availability of computational tools for numerical
integration and parameter estimation, there is no longer any
justification for using Eq. (3).
In an alternative embodiment of the nucleated polymeriza-
tion model, the kinetics of nucleation are postulated to be slow
and essentially irreversible:
nTM Y
knT
AnT Reaction ðR3Þ
Elongation is postulated to be irreversible and independent
of the length of the aggregate, as in Reaction (R2). Applying a
pseudo-steady state assumption to the nucleus concentration,
and assuming that monomer loss by nucleus formation is small
relative to monomer loss by fibril elongation, leads to a
simplified set of differential equations:
 d½M 
dt
¼ ke M½  F½  ð4Þ
d½F
dt
¼ kn

M
nT ð5Þ
Note the similarity between Eqs. (4) and (5) and Eqs. (1) and
(2). Unless n* is known by completely independent means, one
cannot discriminate between the case of unfavorable thermo-
dynamics and slow initiation kinetics by measuring only the
Fig. 2. A comparison of the approximate (Eq. (3)) and numerical (Eq. (1)+ Eq.
(2)) solution to the nucleated polymerization model, where assembly of the
nucleus is assumed to be thermodynamically unfavorable. Model parameters
were set at ke=10,000 M
−1 s−1 and either n*=1 and Kn= 10
−9 (first-order) or
n*=6 and Kn=10
11 M−5 (sixth order).
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time.
The mathematics of the nucleated polymerization model is
analyzed in detail by Powers and Powers [65]. In particular,
they demonstrate that fibril formation by the nucleated
polymerization mechanism may take various forms in different
concentration regimes, and that the rate of fibril formation
becomes independent of concentration under some conditions.
3.2. Monomer conversion
In one version of the monomer conversion model, we
postulate that slow conversion of a native monomer M to an
amyloidogenic monomer A
M Y
ks
A Reaction ðR4Þ
is followed by collision between native monomer and amy-
loidogenic species (monomer), leading to rapid conversion of
the native to the amyloidogenic;
M þ A Ykf 2A Reaction ðR5Þ
The monomer conversion mechanism could also be
considered as an “autocatalytic” process, because the amyloi-
dogenic monomer A increases the rate of conversion of M to A.
Notice that this model does not explicitly include a term for the
further assembly of A into fibrils. There is a simple analytic
expression for this system of equations [60].
M ¼ M0t1 ksðe
ðksþkfM0Þt  1Þ
kseðksþkfM0Þ
t þ kfM0
b ð9Þ
where M0 is the initial concentration of monomer M. The
monomer conversion model was used to describe insulin
aggregation and the effects of inhibitors [60].3.3. Templated assembly
The “templated assembly” model describes elongation of
pre-existing fibrils by reversible addition of monomer:
M þ F ⇄k1
k1 F Reaction ðR6Þ
Since F is constant, evaluation of (R6) produces an analytical
expression
M ¼ M0ek1Ft þ k1k1 1 e
k1Ft  ð10Þ
At long time, the monomer concentration approaches the
ratio of the rate constants k−1/k1=Kd, whereKd is the equilibrium
dissociation constant for monomer-fibril binding.
Aβ fibril elongation rates have been measured using a
number of experimental tools including thioflavin T binding
[66], radioiodinated peptide [67] and surface plasmon reso-
nance [53,54]. The data were analyzed to derive quantitative
measures of association and dissociation rate constants. Eq. (10)
was insufficient to describe the data. Rather, multiple conforma-
tional conversion steps post monomer addition were required;
this has been described as a “dock-lock-block” multistep
mechanism [53,54]. Massi and Straub [68] provide a quanti-
tative analysis of the templated assembly data from Maggio and
coworkers [67]. This model postulates a fibril elongation
process that includes monomer diffusion to the tip of the fibril
(the reaction interface), where it undergoes a reversible
conformational change. This change is “locked in”, (rendered
effectively irreversible) once further monomer addition occurs
and the monomer becomes “blocked” (buried) in the fibril.
There is a region at the fibril tip where the deposit is in an
amorphous (or non-amyloid) conformation; thus, the interface
where monomer adsorbs to the surface, and the reaction
interface where conformational change occurs, are separated in
this model. The length of the amorphous tip depends on the
relative rates of adsorption/desorption and conformational
change. The researchers proposed a molecular basis for
interpreting the rate constants obtained from experimental
data, and suggested how their model may be used to understand
and/or predict fibril elongation from mutant Aβ peptides or
under various solvent conditions [68].3.4. Comparison of kinetic models
Monomer depletion curves were calculated for the nucleated
polymerization, monomer conversion, and templated assembly
models at 3 different concentrations for arbitrarily chosen model
parameters. Results are shown in Fig. 3. The similarities in the
curves demonstrate that accurate data at several concentrations
and over the full time scale is required to distinguish among
these different models.
3.5. Generalized kinetic models
Roberts [69] presents a more generalized discussion of
protein aggregation, for which the models described above can
Fig. 3. Representative solutions of the simple classical kinetic models.
Solutions are shown for the nucleated polymerization (●), monomer
conversion (■) and templated assembly (▲) models at (A) 500 μM, (B)
100 μM and (C) 10 μM initial monomer concentration. Model parameters for
nucleated polymerization were ke= 10
4 M−1 s−1, Kn=10
−9 and n*=1. For the
monomer-directed conversion, ks=3.3×10
−6 s−1, and kf =0.833 M
−1 s−1. For
templated assembly, k1=2×10
5 M−1 s−1 and k−1=0.2 s
−1. Fibril concentration
was assumed to scale with the total concentration at 10−11 M fibrils at 10 μM
monomer, 10−10 M fibrils at 100 μM monomer, and 5×10−10 M fibrils at
500 μM monomer.
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tional change is presumed
N X A
where N is the natively-folded protein and A is a partially or
completely unfolded protein that is aggregation prone. Assem-
bly reactions of several types are allowed:
N þ An X Anþ1
Aþ An X Anþ1
Am þ An X Anþm
where An is a species containing n monomers, with 1≤n<∞. In
the general case, the forward and reverse rate constants vary
with n, and the reaction has not reached equilibrium. Several
useful limiting cases are solved and presented [69]. One of the
important conclusions from this study is that it is impossible to
definitely determine the pathway of aggregation by simply
measuring monomer concentration versus time [69].
3.6. Beyond classical models of monomer loss
The classical macroscopic models described above are used
to evaluate kinetic data on monomer loss but do not directly
consider the additional insight that can be gained by examining
the evolution of aggregate size with time. Yet, it is likely that
biological activity correlates with the aggregate size and
morphology, not just the aggregate mass concentration [7–9].
In our group, we developed a kinetic model for Aβ aggregation
(Fig. 4) that describes the increase in both mass of aggregates
and average size of the aggregates as a function of time and
concentration [52]. Both thin (“filaments”) and thick (‘fibrils’)
were included. Initiation was assumed to require a conforma-
tional change and conversion to oligomer, and there were
mechanisms to account for growth via monomer addition, end-
to-end association of small aggregates, and lateral association of
filaments to fibrils. Since the nature (e.g., oligomer vs. filament
vs. fibril) of the aggregate rather than simply the mass of
aggregated material may be important in toxicity, then it follows
that models that consider only the mass of aggregate (as is true
for many of the models) and cannot predict the size and
morphology of the aggregates, is missing an important part of
the story. We used the kinetic model to interpret data on
alteration of aggregation and toxicity by small peptides [15].
Some efforts are underway to put the rate constants in the
various kinetic models on a firmer theoretical footing. Dobson
and coworkers propose what they call a “toy” model for
amyloid formation kinetics [70]. The model considers unfolded
polypeptides as a starting point, and assumes that intramole-
cular attractive forces can be ignored. They assume that the
denatured polypeptide can be described as a freely jointed
chain. Second-order collisions are allowed to occur, with some
fraction of the collisions having the correct orientation and
energetics to “succeed”, e.g., result in an intermolecular
“bond”. Methods for calculating the probabilities of the two
Fig. 4. A kinetic model of Aβ aggregation that explicitly considers conformational change, and oligomer, filaments, and fibrils. The mathematical description of the
model along with model parameters derived from experimental data is detailed in reference [52].
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probability that another chain will not interfere, are outlined.
These methods provide a means to predict rate constants that
are insensitive to the details of polypeptide sequence. The rate
constants are then used in a classic nucleation-elongation
model. Example results of calculations are couched in terms of
hypothesizing that there are 3 points of contact that must be
made for a successful collision. Various scenarios are
investigated, including the effect of spacing of the 3 critical
contact points, and length of the entire chain. Results from the
simulations are used to explain why partially unfolded proteins,
or shorter peptide sequences, are more likely to form amyloid
fibrils than completely denatured proteins. Despite its recog-
nized limitations, the Dobson model takes the nucleation-
elongation framework towards a more solid molecular-level
description.
4. Quantitative “modern” molecular simulations
It is a daunting task to try to simulate, at the atom level,
aggregation of large systems of polypeptides. High-resolution
molecular simulation of protein folding is possible, although
computationally very intensive, for single chains of moderately
sized polypeptides. However, the aggregates we are interested
in contain tens if not hundreds or even thousands of chains. We
will discuss just two interesting efforts in this area. An extensive
recent review is available [71]. The approach taken is to sacri-
fice a highly detailed atomistic picture to gain computational
tractability.A relatively simple 2-D lattice model was used to examine
“conformational propagation” in fibril growth [72]. Residues
were classified simply as H (hydrophobic) and P (polar), and as
A or B, where A pairs preferentially with B and vice versa.
Assemblies of two 16-mers were enumerated and the lowest-
energy packing modes were selected. Extended β-sheet-like
structures were observed; it was hypothesized that this
organization is reminiscent of a protofilament. Importantly, the
model showed evidence for propagation of the extended β-sheet
conformation through monomer addition, that this conformation
was the only one able to propagate, and that these structures arise
in the absence of explicit consideration of realistic geometric
constraints or hydrogen bonding. The simulations further
indicated that the β-sheet conformation was favored when the
natively folded monomeric state was only marginally stable.
A more recent approach is given in [73]. In this simulation,
each polypeptide monomer is modeled as a 10-bead chain. Side
chains are represented as large hydrophobic or polar beads,
while backbone dipoles are represented as partial charges on
small spheres. A free energy profile describing each monomer is
postulated in which energy minima are located in “amyloid-
competent” and “amyloid protected” states. Lag, elongation,
and equilibrium phases were recapitulated in the simulations.
The simulation results demonstrate that the kinetics of fibril
formation depend on the energy difference between the two
states. In this simulation, micellar oligomers, defined as small
aggregates of monomers in the “amyloid protected” state, are
detected for some energy profiles. This result suggests that such
oligomers may indeed be “off-pathway”.
Fig. 5. Schematic illustrating glutamine residue construction in PRIME. The
light-shaded arces indicate directional hydrogen bond donors, the dark-shaded
arcs indicate directional hydrogen bond acceptors, and the hatched regions
indicate hydrophobic shells. Adapted from [75].
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developed by Hall and coworkers [74–77]. Essentially, each
amino acid in the chain is described as a combination of 3
backbone beads (CO, NH and C–) and one or more side chain
beads (Fig. 5). Interaction forces are modeled as square well
potentials, and the ratio of hydrophobic energy to hydrogen
bond energy is used as a single adjustable parameter.
Simulations of systems of polyalanine peptides have generated
intriguing predictions regarding the pathway of aggregation: (a)
large amorphous aggregates form almost immediately, (b) the
amorphous aggregates dissociate readily into β-sheet dimers
and trimers, (c) fibrils emerge as 2 β-sheets align, (d) fibrils
grow simultaneously in both width and length by addition of
monomers, and (e) fibril elongation is favored over fibril
initiation. Results from these simulations share some features
with classic models of aggregation but are not in complete
agreement with any of them, including the nucleation-elonga-
tion model [77]. PRIME simulations of systems of polygluta-
mine peptides reveal a strikingly heterogeneous mix of folds
and morphologies [74,75].
These simulations lack accurate force fields and include
solvent only implicitly, and their reliability has not yet been
rigorously tested. Despite these caveats, these simulations
provide testable predictions about aggregation and should aid in
mechanistic interpretations of kinetic data.
5. Kinetic considerations in interactions of amyloidogenic
proteins with lipid bilayers
Amyloidogenic proteins and peptides can interact with
membranes, and these interactions may be relevant to mechan-
isms of toxicity. Here we briefly describe a few studies that
address two complementary questions: (a) what conformations
and/or morphologies of amyloidogenic proteins and peptides
interact with the bilayers? (b) how does the membrane affect the
kinetics of aggregation?
5.1. Effect of aggregation state on interactions with membranes
The conformation and aggregation state of the amyloido-
genic protein/peptide is of importance in regulating the degree
of interaction with lipid membranes. In one study, adsorption to
liposomes or to cortical homogenates was greater for aggre-
gated than for monomeric Aβ [78]. At somewhat different
conditions, monomeric Aβ bound rapidly but reversibly to
liposomes, whereas aggregated Aβ bound slowly but essen-
tially irreversibly [79]. Solvent-exposed hydrophobic domains
were detected in oligomeric intermediates that were not present
in either monomeric Aβ or in mature fibrils, and only these
intermediates interacted with lipid bilayers, changing their
membrane fluidity [80]. The hypothesis is that assembly into
soluble aggregates generates hydrophobic domains that interact
with membranes, and that these hydrophobic domains disappear
in the insoluble fibrils. A similar observation was made in a
different study, in which it was observed that liposome aggre-
gation caused by Aβ reached a maximum at about 4 hr after
initiation of Aβ aggregation, and decreased when Aβ was agedfor longer periods of time [81]. Similar results have been
obtained with other amyloidogenic systems. With a mutant
huntingtin fragment containing an expanded polyglutamine
domain, soluble oligomeric aggregates of mutant htt, but not
fully formed fibrils, disrupted membrane integrity [82]. As
another example, α-synuclein is a natively unfolded protein
associated with Parkinson's disease. β-sheet rich oligomers
(protofibrils) of α-synuclein bound to liposomes with high
affinity and caused transient permeabilization of vesicles; no
such effect was observed with monomeric or fibrillar α-
synuclein [83]. However, a different situation was observed
with islet amyloid polypeptide (IAPP), a peptide that forms
amyloid deposits in the pancreas which contribute to type 2
diabetes. With IAPP, the monomer inserted into membranes
readily, whereas fibrillar IAPP was unable to insert [84].
The chemical make-up of the membrane has some effect on
the outcome of protein–lipid interactions, which may account
for some variability in results. For example, at low cholesterol
content, Aβ remained on the surface in a β-sheet structure. At
high cholesterol levels, however, Aβ inserted into the
membrane and underwent a shift to a helical secondary
structure. Assembly into filaments was virtually eliminated
[85]. As another example, protofibrils of α-synuclein bound to
liposomes of acidic but not neutral phospholipids [83].
5.2. Effect of membranes on aggregation kinetics
Several studies demonstrate that the lipid bilayer actively
changes fibril kinetics. For example, the lipid bilayer
facilitated nucleation of Aβ fibrils in one study, with the
effect depending on the chemical composition of the lipids
[86]. Liposomes accelerated fibrillogenesis of mutant N-
terminal huntingtin fragment [82]. Analysis of data from
transgenic mice led one group of researchers to conclude that
membrane binding was necessary for exponential growth
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cases, lipids may inhibit aggregation. In one study it was
observed that bovine insulin adsorbed to lipid surfaces, with
kinetics that depended on the charge of the lipid head groups
[88]. Adsorption accelerated the rate of unfolding of insulin,
and inhibited conversion to β-sheet and growth of amyloid
fibrils, relative to the bulk solution [88], probably due to
favorable interactions between the unfolded protein and the
lipid bilayer surface. Another group analyzed the kinetics of
Aβ aggregation in the absence and presence of liposomes,
using a nucleated polymerization model, and reported that
neutral liposomes decreased the nucleation rate constant [89].
Using micelle-forming surfactants as model membranes, one
group showed that surfactants below their critical micelle
concentration (CMC) shortened the fibrillogenesis lag time
while the opposite effect was observed above the CMC [90].
Micelles delayed, but did not prevent, aggregation.
In a further twist, the initial conformation and aggregation
state of the peptide/protein may influence the subsequent effect
of the lipid bilayer on aggregation kinetics. If Aβ fibrils
assembled from monomers that were adsorbed to the surface of
the membrane, disruption of membrane integrity was detected;
preformed fibrils, although they adsorbed to bilayers, did not
disturb the bilayer. Monomeric Aβ partially inserted into the
bilayer [86]. If Aβ inserted, then aggregation was inhibited,
whereas binding of Aβ to membrane surfaces may accelerate
fibrillogenesis [91].
All of the challenges of measuring and modeling the
kinetics of aggregation remain, with the added complexity of
a two-way conversation between membrane and protein:
association with the membrane depends on, and influences,
the conformation and aggregation state of the protein.
Furthermore, the chemical composition and physical proper-
ties of the membrane affects membrane–protein interactions.
Elucidation of the intricate kinetic interplay between
amyloidogenesis and membranes provides a challenge that
will need to be addressed to completely ascertain the role of
membranes in amyloid disease pathology.
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